Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

Heidelberg Pharma (Group)

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs, as well as in third-party collaborations, to create a variety of ATAC candidates. The proprietary lead candidate is HDP-101, a BCMA ATAC for multiple myeloma. The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON® and REDECTANE®, while RENCAREX® is available for out-licensing and further development. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. *


Period Start 2017-10-18 renamed
  Predecessor Wilex (Group)
Products Industry cancer drug
  Industry 2 cancer test
Persons Person Schmidt-Brand, Jan (Wilex 201404– CEO before CFO + Heidelberg Pharma 200109– CEO + CFO)
  Person 2 Wilhelm, Olaf Georg (Therawis 201405– Managing Director before Wilex 2001–201403 CEO)
Region Region Ladenburg
  Country Germany
  Street 22 Gregor-Mendel-Str.
  City 68526 Ladenburg
    Address record changed: 2020-12-12
Basic data Employees C: 51 to 100 (2018-11-30)
  Currency EUR
  Annual sales 4,373,456 (income, total, consolidated (2017/18) 2018-11-30)
  Profit -11,671,980 (2018-11-30)
  Cash 19,440,352 (2018-11-30)
    * Document for �About Section�: Heidelberg Pharma AG. (10/19/17). "Press Release: Wilex AG Successfully Completes Change of Name to Heidelberg Pharma AG". Ladenburg.
Record changed: 2020-12-12


Picture [iito] Made Without Love 650x80px

More documents for Heidelberg Pharma (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top